Bli medlem
Bli medlem

Du är här


Trading of Initiator Pharma shares on Nasdaq First North Growth market starts today

Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today, October 25, 2021, first trading day at Nasdaq First North Growth Market and new website.

Commencing today, Initiator Pharma shares are traded at the Nasdaq First North Growth Market under the ticker INIT with ISIN DK0060775872. Shareholders in Initiator Pharma will not have to take any action with regards to the change of listing venue. In connection with the list change the company has announced an updated website,
I appreciate how Nasdaq First North has welcomed Initiator Pharma in our journey towards making a difference for patients who suffers from erectile dysfunction or neuropathic pain. We see the list change as a natural progression for our ambition to create a global awareness of our programs and the significant unmet needs they address. The new market place makes the Initiator Pharma share accessible for the many international investors who use the Nasdaq platforms,” says Claus Elsborg Olesen, CEO of Initiator Pharma. “We are looking forward to reach and deliver on several significant milestones over the next 18 months. These deliverables will be transformational for Initiator Pharma, benefitting the company and its shareholders. We are welcoming you all to take part in our exciting journey.”
Redeye AB has been appointed as the company’s Certified Adviser on Nasdaq First North. In connection with the list change, DLA Piper Denmark and DLA Piper Sweden have acted as the company’s legal advisor.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address and phone number +46 8 121 576 90, is the company’s Certified Adviser. For more information, please visit


Trading of Initiator Pharma shares on Nasdaq First North Growth market starts today

Författare MFN